Konstantin K. Laktionov
Moscow, MOW 115522, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.
Journal: Exploration of targeted anti-tumor therapy
Published: December 16, 2025
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 16, 2025
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 04, 2025
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2025
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 07, 2025
FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer.
FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer.
Journal: Frontiers in immunology
Published: March 03, 2025
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.
Journal: Future oncology (London, England)
Published: February 25, 2025
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 13, 2024
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Journal: Nature medicine
Published: September 09, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 01, 2024
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 05, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 28, 2024
Last Updated: 09/26/2026